Login to Your Account

Phase III So Far, So Good, but . . .

Amgen's Early Melanoma Data: Analysts 'Overall' in Wait Mode

By Randy Osborne
Staff Writer

Thursday, March 21, 2013
Amgen Inc.'s $1 billion buyout in 2011 of BioVex Group Inc., which brought aboard the melanoma therapy then known as OncoVex, may be paying off, but analysts are waiting for overall survival (OS) Phase III data before they start jumping up and down about the compound, now called talimogene laherparepvec, or T-VEC.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription